OLMA
Olema Pharmaceuticals, Inc. NASDAQ Listed Nov 19, 2020$15.13
Pre-mkt
$15.17
+0.26%
Mkt Cap $1.3B
52w Low $3.89
34.7% of range
52w High $36.26
50d MA $16.55
200d MA $16.03
P/E (TTM)
-7.7x
EV/EBITDA
-11.9x
P/B
2.6x
Debt/Equity
0.0x
ROE
-34.0%
P/FCF
-14.8x
RSI (14)
—
ATR (14)
—
Beta
2.18
50d MA
$16.55
200d MA
$16.03
Avg Volume
1.6M
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
512 2nd Street · San Francisco, CA 94107 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.51 | -0.50 | +2.0% | 16.60 | -1.7% | -9.3% | -12.2% | -9.9% | -15.2% | -15.8% | — |
| Nov 10, 2025 | AMC | -0.44 | -0.49 | -11.4% | 8.70 | -0.7% | -5.9% | -7.4% | -8.7% | -3.4% | -2.1% | — |
| Aug 11, 2025 | AMC | -0.43 | -0.51 | -18.6% | 4.57 | +7.9% | +16.2% | +15.3% | +15.1% | +20.6% | +26.0% | — |
| May 13, 2025 | AMC | -0.49 | -0.36 | +26.5% | 4.68 | +6.2% | -3.8% | +0.2% | +0.6% | +2.6% | +8.5% | — |
| Mar 18, 2025 | AMC | -0.63 | -0.51 | +19.0% | 4.14 | +10.4% | -0.7% | -0.5% | +2.2% | +4.3% | +1.2% | — |
| Nov 12, 2024 | AMC | -0.59 | -0.60 | -1.7% | 11.54 | +3.0% | -0.5% | -12.5% | -20.5% | -25.2% | -24.4% | — |
| Aug 6, 2024 | AMC | -0.54 | -0.54 | +0.0% | 13.94 | +2.2% | -9.9% | -8.6% | -15.0% | -12.5% | -10.1% | — |
| May 8, 2024 | AMC | -0.53 | -0.56 | -5.7% | 10.85 | +5.1% | -9.3% | -14.1% | -15.0% | -6.3% | -9.2% | — |
| Mar 11, 2024 | AMC | -0.49 | -0.49 | +0.0% | 13.00 | +0.2% | -6.6% | -3.8% | -11.0% | -11.2% | -14.8% | — |
| Nov 7, 2023 | AMC | -0.51 | -0.48 | +5.9% | 16.62 | +1.2% | +3.1% | -2.8% | -4.8% | -11.3% | -4.5% | — |
| Aug 8, 2023 | AMC | -0.73 | -0.49 | +32.9% | 9.46 | +1.4% | +12.1% | +7.0% | +10.8% | +9.2% | +14.3% | — |
| May 9, 2023 | AMC | -0.66 | -0.70 | -6.1% | 7.27 | -3.4% | -8.7% | -6.5% | -4.1% | -8.0% | -12.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $15.06 | $15.33 | +1.8% | -3.3% | -0.7% | -6.5% | -7.2% | -7.5% |
| Mar 18 | Goldman Sachs | Maintains | Buy → Buy | — | $15.06 | $15.33 | +1.8% | -3.3% | -0.7% | -6.5% | -7.2% | -7.5% |
| Mar 17 | Citigroup | Maintains | Buy → Buy | — | $16.60 | $16.32 | -1.7% | -9.3% | -12.2% | -9.9% | -15.2% | -15.8% |
| Mar 17 | Guggenheim | Maintains | Buy → Buy | — | $16.60 | $16.32 | -1.7% | -9.3% | -12.2% | -9.9% | -15.2% | -15.8% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.55 | $13.54 | -37.2% | -25.8% | -26.9% | -27.6% | -30.8% | -31.7% |
| Dec 12 | Citigroup | Maintains | Buy → Buy | — | $31.58 | $32.14 | +1.8% | +4.7% | +13.5% | +8.5% | +3.2% | -2.4% |
| Dec 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $30.68 | $30.22 | -1.5% | +2.9% | +7.7% | +16.8% | +11.7% | +6.3% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.68 | $30.22 | -1.5% | +2.9% | +7.7% | +16.8% | +11.7% | +6.3% |
| Dec 11 | Goldman Sachs | Maintains | Buy → Buy | — | $30.68 | $30.22 | -1.5% | +2.9% | +7.7% | +16.8% | +11.7% | +6.3% |
| Nov 21 | Goldman Sachs | Maintains | Buy → Buy | — | $22.01 | $21.49 | -2.4% | +5.3% | +13.8% | +18.4% | +27.8% | +28.7% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $8.52 | $26.46 | +210.6% | +136.4% | +128.1% | +158.3% | +171.9% | +194.0% |
| Nov 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.52 | $26.46 | +210.6% | +136.4% | +128.1% | +158.3% | +171.9% | +194.0% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $26.46 | +210.6% | +136.4% | +128.1% | +158.3% | +171.9% | +194.0% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.36 | $7.28 | -22.2% | -17.0% | -11.5% | -12.5% | -13.6% | -14.2% |
| Sep 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.47 | $6.43 | -0.6% | -2.8% | -1.9% | +28.4% | +17.2% | +15.0% |
| Aug 14 | JP Morgan | Maintains | Overweight → Overweight | — | $5.27 | $5.27 | +0.0% | -0.2% | +4.6% | +9.3% | +3.0% | +3.4% |
| Aug 12 | Citigroup | Maintains | Buy → Buy | — | $4.57 | $4.93 | +7.9% | +16.2% | +15.3% | +15.1% | +20.6% | +26.0% |
| May 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.68 | $4.97 | +6.2% | -3.8% | +0.2% | +0.6% | +2.6% | +8.5% |
| May 14 | Goldman Sachs | Maintains | Buy → Buy | — | $4.68 | $4.97 | +6.2% | -3.8% | +0.2% | +0.6% | +2.6% | +8.5% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.91 | $4.93 | +0.4% | -0.4% | +2.6% | +5.1% | +7.7% | +14.5% |
| Mar 28 | JP Morgan | Maintains | Overweight → Overweight | — | $4.20 | $4.23 | +0.7% | -2.1% | -10.5% | -20.5% | -20.7% | -20.2% |
| Mar 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.14 | $4.57 | +10.4% | -0.7% | -0.5% | +2.2% | +4.3% | +1.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.14 | $4.57 | +10.4% | -0.7% | -0.5% | +2.2% | +4.3% | +1.2% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.42 | $4.37 | -1.1% | -2.0% | +2.0% | -1.1% | -0.2% | +0.7% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.23 | +0.7% | +1.4% | +6.9% | +9.8% | +5.2% | +3.1% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.41 | $8.39 | -0.2% | -20.1% | -19.7% | -23.4% | -27.0% | -30.4% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.64 | $9.74 | +1.0% | -12.8% | -30.3% | -30.0% | -33.2% | -36.3% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.54 | $11.89 | +3.0% | -0.5% | -12.5% | -20.5% | -25.2% | -24.4% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.91 | $11.89 | -0.2% | -1.6% | -3.0% | -0.8% | -0.4% | -2.4% |
| Aug 8 | JP Morgan | Maintains | Overweight → Overweight | — | $12.56 | $12.56 | +0.0% | +1.4% | -5.7% | -2.9% | -0.2% | -4.3% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.94 | $14.24 | +2.2% | -9.9% | -8.6% | -15.0% | -12.5% | -10.1% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.94 | $14.24 | +2.2% | -9.9% | -8.6% | -15.0% | -12.5% | -10.1% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.76 | $11.90 | +1.2% | +19.0% | +18.4% | +13.0% | +11.6% | +15.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.17 | $10.82 | +6.4% | -3.1% | -5.0% | -3.2% | -6.4% | -8.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.85 | $11.40 | +5.1% | -9.3% | -14.1% | -15.0% | -6.3% | -9.2% |
| Mar 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.00 | $13.02 | +0.2% | -6.6% | -3.8% | -11.0% | -11.2% | -14.8% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $13.02 | +0.2% | -6.6% | -3.8% | -11.0% | -11.2% | -14.8% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.75 | $12.74 | -0.1% | -5.2% | -7.9% | -0.9% | -17.3% | -13.9% |
| Sep 15 | JP Morgan | Maintains | Overweight → Overweight | — | $12.15 | $12.64 | +4.0% | +6.1% | +3.5% | +4.0% | -0.5% | -1.0% |
| Sep 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.68 | $12.68 | +0.0% | -7.0% | -9.6% | -8.0% | -2.4% | -5.6% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.61 | $10.75 | +1.3% | +19.5% | +11.1% | +8.0% | +10.0% | +16.7% |
| Aug 10 | JP Morgan | Maintains | Overweight → Overweight | — | $10.60 | $10.72 | +1.1% | -4.5% | -1.1% | -2.5% | +2.0% | -10.2% |
| Aug 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $9.46 | $9.59 | +1.4% | +12.1% | +7.0% | +10.8% | +9.2% | +14.3% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.46 | $9.59 | +1.4% | +12.1% | +7.0% | +10.8% | +9.2% | +14.3% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.64 | $6.71 | +1.1% | +2.4% | +5.0% | +0.8% | -4.5% | +4.7% |
| Mar 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $3.76 | $4.33 | +15.2% | +3.5% | +4.5% | +3.7% | +5.9% | +1.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.76 | $4.33 | +15.2% | +3.5% | +4.5% | +3.7% | +5.9% | +1.3% |
| Feb 22 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.16 | $4.64 | +11.5% | +9.6% | +4.1% | -1.4% | -6.5% | -1.4% |
| Jun 10 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $4.34 | $4.23 | -2.5% | -0.7% | -15.4% | -22.4% | -14.5% | -21.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.60 | $4.40 | -4.3% | +1.7% | +17.0% | +18.0% | +5.9% | -2.2% |
No insider trades available.
8-K · 1.01
!! High
Olema Pharmaceuticals, Inc. -- 8-K 1.01: Material Agreement
Olema Pharmaceuticals entered into a material agreement with KR Oyster Point II, LLC, though specific terms require additional disclosure review to assess financial implications for shareholders.
May 1
8-K · 5.02
!!! Very High
Olema Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Dr. Prakash Raman joined Olema Pharmaceuticals' board as a Class II director, expanding the company's leadership expertise effective April 28, 2026.
Apr 29
8-K
Unknown — 8-K Filing
Olema advanced its lead breast cancer candidate palazestrant through multiple clinical regimens in 2025, signaling progress toward potential commercialization that could validate the company's pipeline and justify its biotech valuation.
Mar 16
Data updated apr 26, 2026 5:16pm
· Source: massive.com